Adjusted EPS was $0.63, which missed the consensus of $0.64.
The adjusted gross profit margin was 80.5% for the quarter, compared to 75.9% in 2Q21.
Transcatheter aortic valve replacement sales grew to $907 million, up 1%. Globally, the company’s average selling price and market position were stable.
Surgical Structural Heart sales were $229 million, down 4% Y/Y.
EW’s cash, cash equivalents, and short-term investments totaled $1.5 billion as of June 30, 2022.
3Q22 Guidance: Edwards Lifesciences expects revenue of $1.30 billion and $1.37 billion (consensus $1.44 billion) and adjusted EPS of $0.58 to $0.66 (consensus $0.65).
FY22 Guidance: Edwards Lifesciences expects sales of $5.35 billion to $5.55 billion (prior $5.5 billion – $6.0 billion) vs. consensus of $5.71 billion and adjusted EPS of $2.50 – $2.65 (consensus of $2.56).
Price Action: EW shares are trading lower by 5.86% at $101 during the post-market session on Thursday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
